PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

Inclusion Criteria: * Adults aged ≥ 60 or aged 50 to 59 with comorbidities (HCT-CI10 score ≥ 3), * Hematological malignancies except myeloproliferative syndrome and myelodysplastic syndrome, * Patient having received an allograft within ≤ 35 days, performed with the following modalities: * First allogeneic transplant, * Haploidentical donor, * Peripheral stem cell transplant, * Non-myeloablative "Baltimore"-type conditioning, delivered as standard in routine care, as reported in the literature (fludarabine, cyclophosphamide, total body irradiation), * Standard GVHD prophylaxis in the context of haploidentical transplants (post-transplant cyclophosphamide, ciclosporin A and mycophenolate mofetil). * Patient discharged from aplasia within ≤ 35 days, * Signed informed consent form, * Affiliation with a social security. Exclusion Criteria: * Previous allogeneic or organ transplant, * Presence of signs of GVHD, * Contraindications to treatment with Thymoglobuline®, * Hypersensitivity to rabbit proteins or to any of the excipients listed in the "Composition" section of the summary of product characteristics, * Pregnant women or may become pregnant (without effective contraception) or breast-feeding, * Persons in emergency situations or unable to give informed consent form, * Adult with a legal protection measure (adult under guardianship, curatorship or safeguard of justice), * Unable to comply with medical follow-up for geographical, social or psychological reasons.